Search company, investor...

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Series A | Alive

Total Raised


Last Raised

$150M | 4 yrs ago

About Curon Biopharmaceutical

Curon Biopharmaceutical (同润生物) is a drug developer focused on cancer immuno-therapies.

Curon Biopharmaceutical Headquarters Location

3rd Floor, Building 1, Fangchun Road No.400 Free Trade Pilot Zone

Shanghai, Shanghai,


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Curon Biopharmaceutical

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Curon Biopharmaceutical is included in 3 Expert Collections, including Biopharma Tech.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.



3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Latest Curon Biopharmaceutical News

Curon and Rhizen ink $149.5 million agreement for tenalisib

Oct 20, 2020

October 20, 2020 HONG KONG – La Chaux-de-Fonds, Switzerland-based Rhizen Pharmaceuticals SA has agreed to license its dual PI3K delta and gamma inhibitor tenalisib (RP-6530) to Shanghai-based Curon Biopharmaceutical Ltd. for as much as $149.5 million, inclusive of an upfront payment of undisclosed value and potential milestone payouts. The Swiss company also stands to receive double-digit royalties on annual net sales of the drug in Greater China.

  • When was Curon Biopharmaceutical founded?

    Curon Biopharmaceutical was founded in 2018.

  • Where is Curon Biopharmaceutical's headquarters?

    Curon Biopharmaceutical's headquarters is located at 3rd Floor, Building 1, Fangchun Road No.400, Shanghai.

  • What is Curon Biopharmaceutical's latest funding round?

    Curon Biopharmaceutical's latest funding round is Series A.

  • How much did Curon Biopharmaceutical raise?

    Curon Biopharmaceutical raised a total of $150M.

  • Who are the investors of Curon Biopharmaceutical?

    Investors of Curon Biopharmaceutical include Temasek, Boyu Capital and 6 Dimensions Capital.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.